NASDAQ:ASND

Ascendis Pharma A/S News Headlines

$121.95
-2.23 (-1.80 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$121.03
Now: $121.95
$126.43
50-Day Range
$123.37
MA: $138.91
$158.66
52-Week Range
$120.02
Now: $121.95
$183.98
Volume307,200 shs
Average Volume207,189 shs
Market Capitalization$6.55 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.77

Headlines

Ascendis Pharma A/S (NASDAQ ASND) News Headlines Today

SourceHeadline
Ascendis Pharma A/S (NASDAQ:ASND) Rating Lowered to Market Perform at OppenheimerAscendis Pharma A/S (NASDAQ:ASND) Rating Lowered to Market Perform at Oppenheimer
marketbeat.com - March 30 at 7:53 AM
RSI Alert: Ascendis Pharma (ASND) Now OversoldRSI Alert: Ascendis Pharma (ASND) Now Oversold
nasdaq.com - April 15 at 8:08 PM
Oppenheimer Downgrades Ascendis Pharma A/S (NASDAQ:ASND) to Market PerformOppenheimer Downgrades Ascendis Pharma A/S (NASDAQ:ASND) to Market Perform
americanbankingnews.com - March 30 at 8:36 AM
Ascendis Pharma A/S Presents 6-Month Open-Label Extension Data from Phase 2 PaTH Forward Trial of TransCon PTH in Adult Hypoparathyroidism at ENDO 2021Ascendis Pharma A/S Presents 6-Month Open-Label Extension Data from Phase 2 PaTH Forward Trial of TransCon PTH in Adult Hypoparathyroidism at ENDO 2021
finance.yahoo.com - March 23 at 9:27 AM
Ascendis Pharma A/S Announces Participation at Oppenheimer 31st Annual Healthcare ConferenceAscendis Pharma A/S Announces Participation at Oppenheimer 31st Annual Healthcare Conference
benzinga.com - March 15 at 7:12 AM
Ascendis Pharma A/S (ASND) Q4 2020 Earnings Call TranscriptAscendis Pharma A/S (ASND) Q4 2020 Earnings Call Transcript
finance.yahoo.com - March 11 at 5:58 AM
Ascendis Pharma A/S Reports Full Year 2020 Financial ResultsAscendis Pharma A/S Reports Full Year 2020 Financial Results
finance.yahoo.com - March 10 at 6:05 PM
Ascendis Pharma A/S Announces Seven Presentations at ENDO 2021, Demonstrating Commitment to People with Rare Endocrine DiseasesAscendis Pharma A/S Announces Seven Presentations at ENDO 2021, Demonstrating Commitment to People with Rare Endocrine Diseases
finance.yahoo.com - March 10 at 8:04 AM
Ascendis Pharma A/S Announces Seven Presentations at ENDO 2021, Demonstrating Commitment to People with Rare Endocrine DiseasesAscendis Pharma A/S Announces Seven Presentations at ENDO 2021, Demonstrating Commitment to People with Rare Endocrine Diseases
finance.yahoo.com - March 10 at 8:04 AM
Earnings Preview for Ascendis PharmaEarnings Preview for Ascendis Pharma
finance.yahoo.com - March 9 at 2:34 PM
Ascendis Pharma A/S Announces Full Year 2020 Financial Results and Business Update Conference Call on March 10Ascendis Pharma A/S Announces Full Year 2020 Financial Results and Business Update Conference Call on March 10
finance.yahoo.com - March 4 at 6:59 PM
Ascendis Pharma A/S Announces New “Outgrow GHD” Educational Resource to Support Rare Disease Day 2021Ascendis Pharma A/S Announces New “Outgrow GHD” Educational Resource to Support Rare Disease Day 2021
finance.yahoo.com - February 26 at 7:38 AM
Ascendis Pharma A/S Announces Participation at SVB Leerink 10th Annual Global Healthcare ConferenceAscendis Pharma A/S Announces Participation at SVB Leerink 10th Annual Global Healthcare Conference
finance.yahoo.com - February 18 at 5:36 PM
Ascendis Pharma A/S Announces Equity Investment in VISEN PharmaceuticalsAscendis Pharma A/S Announces Equity Investment in VISEN Pharmaceuticals
finance.yahoo.com - January 8 at 11:51 PM
VISEN Pharmaceuticals Closes $150 Million Series B Financing to Accelerate the Development and Commercialization of its Innovative Endocrinology Therapies in Greater ChinaVISEN Pharmaceuticals Closes $150 Million Series B Financing to Accelerate the Development and Commercialization of its Innovative Endocrinology Therapies in Greater China
finance.yahoo.com - January 8 at 11:51 PM
Ascendis Pharma Invests $12.5 Mln In VISEN Pharma Ascendis Pharma Invests $12.5 Mln In VISEN Pharma
markets.businessinsider.com - January 8 at 9:34 PM
Ascendis Pharma A/S Announces Participation in 39th Annual J.P. Morgan Healthcare ConferenceAscendis Pharma A/S Announces Participation in 39th Annual J.P. Morgan Healthcare Conference
benzinga.com - January 4 at 7:29 AM
Ascendis Pharma A/S Announces Filing of Investigational New Drug Application to Initiate TransCon™ TLR7/8 Agonist Clinical ProgramAscendis Pharma A/S Announces Filing of Investigational New Drug Application to Initiate TransCon™ TLR7/8 Agonist Clinical Program
finance.yahoo.com - December 30 at 7:24 PM
Ascendis Pharma A/S Announces Filing of Investigational New Drug Application to Initiate TransCon™ TLR7/8 Agonist Clinical ProgramAscendis Pharma A/S Announces Filing of Investigational New Drug Application to Initiate TransCon™ TLR7/8 Agonist Clinical Program
finance.yahoo.com - December 30 at 7:24 PM
Implied Volatility Surging for Ascendis Pharma (ASND) Stock OptionsImplied Volatility Surging for Ascendis Pharma (ASND) Stock Options
finance.yahoo.com - December 30 at 2:04 PM
Ascendis Pharma A/S Announces Planned Board TransitionAscendis Pharma A/S Announces Planned Board Transition
finance.yahoo.com - December 14 at 5:49 PM
Exclusive: Biotech company Ascendis Pharma leases up new Stanford Research Park buildingExclusive: Biotech company Ascendis Pharma leases up new Stanford Research Park building
bizjournals.com - December 10 at 5:08 PM
Ascendis Pharma A/S Announces Participation at the Evercore ISI 3rd Annual HealthCONx Virtual ConferenceAscendis Pharma A/S Announces Participation at the Evercore ISI 3rd Annual HealthCONx Virtual Conference
markets.businessinsider.com - November 25 at 7:07 AM
Ascendis Pharma: TransCon Platform Is A Major Value DriverAscendis Pharma: TransCon Platform Is A Major Value Driver
seekingalpha.com - November 17 at 11:45 PM
The Ascendis Pharma A/S (NASDAQ:ASND) Third-Quarter Results Are Out And Analysts Have Published New ForecastsThe Ascendis Pharma A/S (NASDAQ:ASND) Third-Quarter Results Are Out And Analysts Have Published New Forecasts
nasdaq.com - November 15 at 9:02 AM
Earnings Update: Ascendis Pharma A/S (NASDAQ:ASND) Just Reported Its Third-Quarter Results And Analysts Are Updating Their ForecastsEarnings Update: Ascendis Pharma A/S (NASDAQ:ASND) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts
finance.yahoo.com - November 15 at 9:02 AM
Ascendis Pharmas (ASND) CEO Jan Mikkelsen on Q3 2020 Results - Earnings Call TranscriptAscendis Pharma's (ASND) CEO Jan Mikkelsen on Q3 2020 Results - Earnings Call Transcript
seekingalpha.com - November 12 at 12:41 AM
Ascendis Pharma A/S (ASND) Q3 2020 Earnings Call TranscriptAscendis Pharma A/S (ASND) Q3 2020 Earnings Call Transcript
fool.com - November 11 at 11:57 PM
Why Earnings Season Could Be Great for Ascendis (ASND)Why Earnings Season Could Be Great for Ascendis (ASND)
finance.yahoo.com - November 10 at 2:12 PM
Catalyst (CPRX) to Report Q3 Earnings: Whats in the Cards?Catalyst (CPRX) to Report Q3 Earnings: What's in the Cards?
finance.yahoo.com - November 4 at 12:21 PM
Sorrento (SRNE) to Report Q3 Earnings: Whats in the Cards?Sorrento (SRNE) to Report Q3 Earnings: What's in the Cards?
finance.yahoo.com - November 4 at 12:21 PM
Ascendis Pharma A/S Announces Third Quarter 2020 Financial Results and Business Update Conference Call on November 11Ascendis Pharma A/S Announces Third Quarter 2020 Financial Results and Business Update Conference Call on November 11
finance.yahoo.com - November 2 at 5:21 PM
Ascendis Pharmas TransCon nabs Europe Orphan drug tag in hypoparathyroidismAscendis Pharma's TransCon nabs Europe Orphan drug tag in hypoparathyroidism
seekingalpha.com - October 23 at 2:50 PM
Ascendis Pharma A/S Receives Orphan Designation for TransCon™ PTH for Treatment of Hypoparathyroidism in EuropeAscendis Pharma A/S Receives Orphan Designation for TransCon™ PTH for Treatment of Hypoparathyroidism in Europe
finance.yahoo.com - October 23 at 8:22 AM
Ascendis Pharma A/S Nav.-Akt.(S (A71.SG)Ascendis Pharma A/S Nav.-Akt.(S (A71.SG)
au.finance.yahoo.com - October 14 at 10:42 PM
Ascendis Pharma A/S Announces Filing of the Clinical Trial Notification for Phase 3 Clinical Trial of TransCon™ hGH for Pediatric Growth Hormone Deficiency in JapanAscendis Pharma A/S Announces Filing of the Clinical Trial Notification for Phase 3 Clinical Trial of TransCon™ hGH for Pediatric Growth Hormone Deficiency in Japan
finance.yahoo.com - September 23 at 8:08 PM
Ascendis Pharma A/S Announces Support for Children’s Growth Awareness Week  and Day 2020Ascendis Pharma A/S Announces Support for Children’s Growth Awareness Week and Day 2020
finance.yahoo.com - September 15 at 6:26 PM
Is Ascendis Pharma A/S (ASND) Going to Burn These Hedge Funds?Is Ascendis Pharma A/S (ASND) Going to Burn These Hedge Funds?
finance.yahoo.com - September 15 at 1:26 PM
Ascendis Pharma A/S Announces Participation at the 18th Annual Morgan Stanley Virtual Global Healthcare ConferenceAscendis Pharma A/S Announces Participation at the 18th Annual Morgan Stanley Virtual Global Healthcare Conference
finance.yahoo.com - September 11 at 7:08 AM
Ascendis Pharma A/S Announces Presentations for TransCon™ PTH and Hypoparathyroidism at American Society for Bone and Mineral Research Annual MeetingAscendis Pharma A/S Announces Presentations for TransCon™ PTH and Hypoparathyroidism at American Society for Bone and Mineral Research Annual Meeting
finance.yahoo.com - September 10 at 10:06 AM
Achondroplasia Treatment Market 2020 Report Including COVID-19 Impact Analysis and Forecast till 2029Achondroplasia Treatment Market 2020 Report Including COVID-19 Impact Analysis and Forecast till 2029
marketwatch.com - September 9 at 3:31 PM
Ascendis Pharma A/S Submits Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for TransCon™ hGH for Treatment of Pediatric Growth Hormone DeficiencyAscendis Pharma A/S Submits Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for TransCon™ hGH for Treatment of Pediatric Growth Hormone Deficiency
finance.yahoo.com - September 8 at 6:40 PM
Hedge Funds Never Been This Bullish On Five9 Inc (FIVN)Hedge Funds Never Been This Bullish On Five9 Inc (FIVN)
finance.yahoo.com - September 7 at 5:29 PM
FDA accepts Ascendis TransCon applicationFDA accepts Ascendis' TransCon application
seekingalpha.com - September 5 at 4:21 AM
Ascendis Pharma A/S Announces U.S. Food and Drug Administration (FDA)  Accepts Biologics License Application (BLA) for TransCon™ hGH  for Pediatric Growth Hormone Deficiency (GHD)Ascendis Pharma A/S Announces U.S. Food and Drug Administration (FDA) Accepts Biologics License Application (BLA) for TransCon™ hGH for Pediatric Growth Hormone Deficiency (GHD)
finance.yahoo.com - September 4 at 1:19 PM
Ascendis Pharma A/S Announces Presentations for TransCon™ PTH and Hypoparathyroidism at 22nd European Congress of EndocrinologyAscendis Pharma A/S Announces Presentations for TransCon™ PTH and Hypoparathyroidism at 22nd European Congress of Endocrinology
finance.yahoo.com - September 4 at 8:19 AM
Ascendis Pharma A/S Announces Participation at the 2020 Wells Fargo Virtual Healthcare ConferenceAscendis Pharma A/S Announces Participation at the 2020 Wells Fargo Virtual Healthcare Conference
finance.yahoo.com - September 2 at 8:35 PM
Ascendis Pharma A/S (ASND) Q2 2020 Earnings Call TranscriptAscendis Pharma A/S (ASND) Q2 2020 Earnings Call Transcript
finance.yahoo.com - August 28 at 1:33 AM
Ascendis Pharma EPS misses by €0.50, misses on revenueAscendis Pharma EPS misses by €0.50, misses on revenue
seekingalpha.com - August 27 at 8:33 PM
Ascendis Pharma A/S Reports Second Quarter 2020 Financial Results and Announces New Data from the Four-Week, Fixed Dose, Double-Blind Portion of the PaTH Forward TrialAscendis Pharma A/S Reports Second Quarter 2020 Financial Results and Announces New Data from the Four-Week, Fixed Dose, Double-Blind Portion of the PaTH Forward Trial
finance.yahoo.com - August 27 at 8:33 PM
Ascendis Pharma: Q2 Earnings InsightsAscendis Pharma: Q2 Earnings Insights
finance.yahoo.com - August 27 at 8:33 PM
This page was last updated on 4/19/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.